The in vitro inhibition of human CYP1A2, CYP2D6 and CYP3A4 by tetrahydropalmatine, neferine and berberine

Phytotherapy Research

Volumn 26, Issue 2, 2012, Pages 277-283

  Zhao, Yong ^a,b   Hellum, Bent Håvard ^b   Liang, Aihua ^a   Nilsen, Odd Georg ^b  

^a INSTITUTE OF CHINESE MATERIA MEDICA   (China)

^b NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

Author keywords

CYP inhibition; IC 50; in vitro; purified herbal constituents

Indexed keywords

ALPHA NAPHTHOFLAVONE; BERBERINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; KETOCONAZOLE; NEFERINE; PHENACETIN; QUINIDINE; TESTOSTERONE; TETRAHYDROPALMATINE;

ARTICLE; CHEMICAL INTERACTION; CONTROLLED STUDY; DRUG ISOLATION; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IC 50; IN VITRO STUDY; PROTEIN EXPRESSION;

BENZYLISOQUINOLINES; BERBERINE; BERBERINE ALKALOIDS; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 CYP3A; ENZYME INHIBITORS; HUMANS; INHIBITORY CONCENTRATION 50; MOLECULAR STRUCTURE; PLANT EXTRACTS;

ZIZIPHUS MAURITIANA;

EID: 84856239112     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.3554     Document Type: Article

References (31)

1. Bian CP, Xing SH, Teng YD, Xu PC,. 1984. Interaction of tetrahydropalmatine combination with dihydroetor and B-7601. Acta Acad Med Xuzhou 4 (2): 26-29.
2. Bjornsson TD, Callaghan JT, Einolf HJ, et al,. 2003. The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective. Drug Metab Dispos 31 (7): 815-832. (Pubitemid 36759050)
3. Burk O, Koch I, Raucy J, et al,. 2004. The induction of cytochrome P450 3A5 (CYP3A5) in the human liver and intestine is mediated by the xenobiotic sensors pregnane X receptor (PXR) and constitutively activated receptor (CAR). J Biol Chem 279 (37): 38379-38385. (Pubitemid 39295987)
4. Cao JG, Tang XQ, Shi SH,. 2004. Multidrug resistance reversal in human gastric carcinoma cells by neferine. World J Gastroenterol 10: 3062-3064.
5. Chatterjee P, Franklin MR,. 2003. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 31: 1391-1397. (Pubitemid 37310329)
6. Chen J, Liu JH, Wang T, Xiao HJ, Yin HP, Yang J,. 2008. Effects of plant extract neferine on cyclic adenosine monophosphate and cyclic guanosine monophosphate levels in rabbit corpus cavernosum in vitro. Asian J Androl 10 (2): 307-312. (Pubitemid 351337995)
7. Cloe S,. 2010. Cytochrome P450 inhibition assay.
8. Elmer GW, Lafferty WE, Tyree PT, Lind BK,. 2007. Potential interactions between complementary/alternative products and conventional medicines in a medicare population. Ann Pharmacother 41: 1617-1624. (Pubitemid 47479790)
9. Ernst E,. 1998. Harmless herbs? A review of the recent literature. Am J Med 104: 170-178. (Pubitemid 28117413)
10. Gao XX, Zheng SQ,. 2006. Effect on the activity of cytochrome P450 by herbs co-administrated with drug. J North China Coal Med Coll 8 (3): 333-335.
11. Hellum BH, Hu ZH, Nilsen OG,. 2007. The induction of CYP1A2, CYP2D6 and CYP3A4 by six trade herbal products in cultured primary humen hepatocytes. Basic Clin Pharmacol Toxicol 100: 23-30. (Pubitemid 46051439)
12. Hiroshi I, Yasuhiro T, Shigetoshi K, Akira H, Tadashi W,. 2004. Identification and characterization of potent CYP3A4 inhibitions in Cshisandra fruit extract. Drug Metab Dispos 32 (12): 1351-1358.
13. Hong ZY, Fan GR, Chai YF, Yin XP, Wen J, Wu YT,. 2005. Chiral liquid chromatography resolution and stereoselective pharmacokinetic study of tetrahydropalmatine enantiomers in dogs. J Chromatogr B 826: 108-113. (Pubitemid 41446440)
14. Hu YJ, Liu Y, Xiao XH,. 2009. Investigation of the interaction between berberine and human serum albumin. Biomacromolecules 10: 517-521.
15. Huang Y, Bai Y, Zhao LB, et al,. 2007. Pharmacokinetics and metabolism of neferine in rats after a single oral administration. Biopharm Drug Dispos 28: 361-372. (Pubitemid 350020227)
16. Li JK, He F, Bi HC, et al,. 2008. Inhibition of human cytochrome P450 CYP1A2 by flavonoids: a quantitative structure activity relationship study. Acta Pharma Sin 43 (12): 1198-1204.
17. Li Y, You XP, Jiang JD,. 2008. Progress in pharmacokinetic researches of berberine. Chinese J New Drugs 17 (9): 733-738.
18. Marjo J, Ka R, Pertti J, Neuvonen T, Janne TB,. 2007. Tolfenamic acid is a potent CYP1A2 inhibitor in vitro but does not interact in vivo: correction for protein binding is needed for data interpretation. Eur J Clin Pharmacol 63: 829-836.
19. Rendic S, Di Carlo FJ,. 1997. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrates, inducers, and inhibitors. Drug Metab Rev 29 (1-2): 413-580. (Pubitemid 27293618)
20. Shen GL, Liang AH, Zhao Y, et al,. 2009. Interaction between four herb constituents and a western drug by CYP3A4 enzyme metabolism in vitro. China J Chinese Mat Med 34 (13): 1705-1711.
21. Soraya M, Paine MF, Lydia L, Kenneth E, Thummel D, Shen D,. 1999. Comparison of CYP2D6 Content and Metoprolol Oxidation Between Microsomes Isolated from Human Livers and Small Intestines. Pharmaceut Res 16 (8): 1199-1205. (Pubitemid 29393607)
22. Strobl GR, von Kruednener S, Stockigt J, Guengerich FP, Wolf T,. 1993. Development of a pharmacophore for inhibition of human liver cytochrome P4502D6: molecular modeling and inhibition studies. J Med Chem 36: 1136-1145. (Pubitemid 23159287)
23. Subehan S, Kadota S, Tezuka Y,. 2008. In vitro mechanism-based inactivation of cytochrome P450 3A4 by a new constituent of Cinnamomum burmani. Planta Med 74 (12): 1474-1480.
24. Sundberg IM,. 2004. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 25: 193-200.
25. Wu XC, Li Q, Xin HW,. 2001. The pharmacokinetics of enhancement of cyclosporin A by berberine chloride c~administrated in renal transplanted recipients. Asian J Drug Metab Pharmacokinet 1 (4): 257-261.
26. Xu T, Chao HM, Jin ZL,. 2000. Study progress of clinical application of tetrahydropalmatine. Acta Univ Trad Med Sin Pharmacol 14 (4): 60-63.
27. Zhang JF, Tan L, Zhou JH, Lu XH, Yuan YS,. 1998. Determination of rotundine in human plasma by HPLC and pharmacokinetic studies. J China Pharmaceut Univ 29 (1): 67-70.
28. Zhang QY, Dunbar D, Ostrowska A, Zeisloft S, Yang J, Kaminsky LS,. 1999. Characterization of human small intestinal cytochromes P450. Drug Metab Dispos 27: 804-809. (Pubitemid 29297778)
29. Zhao LB, Wang XM, Wu JH, et al,. 2007. Improved RP-HPLC method to determine neferine in dog plasma and its application to pharmacokinetics. J Chromatogr B 857: 341-346.
30. Zhao X, Zhang JJ, Wang X, Bu XY, Lou YQ, Zhang GL,. 2008. Effect of berberine on hepatocyte proliferation, inducible nitric oxide synthase expression, cytochrome P450 2E1 and 1A2 activities in diethylnitrosamine- and phenobarbital-treated rats. Biomed Pharmacother 62: 567-572.
31. Zheng BB, Wei J, Jiang JD, Gong HH, Zhang RS,. 2009. The therapeutic effects of combination of simvastatin with berberine on the patients with hyperlipemia. Acta Univ Med Nanjing (Nat Sci) 11: 1493-1497.